Femasys Reports Q1 2026 Profit Turnaround, Advances Fertility and Birth Control Portfolio

Event summary

  • Femasys reported a net income of $846,100 for Q1 2026, reversing a $5.9M loss in the same period last year.
  • Sales increased 24.5% to $424,889, driven by FemBloc product sales.
  • R&D expenses dropped 55.9% to $1.3M as development products transitioned to commercialization.
  • FemBloc initiated patient enrollment in the FINALE pivotal clinical trial for U.S. FDA approval.
  • FemaSeed Complete launched at ACOG 2026, expanding OB/GYN adoption of first-line fertility treatment.

The big picture

Femasys is executing a strategic shift from R&D to commercialization, positioning itself as a key player in accessible fertility solutions. The company's focus on OB/GYN office integration for first-line treatments aligns with broader healthcare trends toward decentralized, cost-effective care. With international partnerships expanding its reach, Femasys aims to capitalize on unmet needs in both fertility treatment and non-surgical birth control.

What we're watching

Commercialization Pace
Whether Femasys can sustain its 24.5% revenue growth as it scales FemaSeed and FemBloc adoption.
Regulatory Milestones
The timeline for FemBloc's U.S. FDA approval following FINALE trial completion.
Cash Runway
How Femasys will extend its cash position beyond Q3 2026 given current burn rate.